News Releases
All Releases
View Summary Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress
Sep 21, 2016
PDF 18.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent Developments
Sep 8, 2016
PDF 37.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Sep 6, 2016
PDF 14.6 KB Add to Briefcase
View Summary National Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals' Bavituximab in Multiple Cancers
Sep 6, 2016
PDF 25.8 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016
Sep 1, 2016
PDF 15.3 KB Add to Briefcase
View Summary Avid Bioservices to Participate in Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit
Aug 9, 2016
PDF 17.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments
Jul 14, 2016
PDF 42.9 KB Add to Briefcase
View Summary Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center
Jul 14, 2016
PDF 19.6 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 2016
Jul 7, 2016
PDF 15.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Jun 2, 2016
PDF 14.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
Jun 2, 2016
PDF 23.7 KB Add to Briefcase
View Summary Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)
Apr 20, 2016
PDF 19.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
Mar 9, 2016
PDF 37.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Mar 7, 2016
PDF 14.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility
Mar 7, 2016
PDF 17.7 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
Mar 3, 2016
PDF 15.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab
Feb 25, 2016
PDF 18.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
Jan 20, 2016
PDF 19.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
Jan 11, 2016
PDF 23.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
Jan 6, 2016
PDF 22.8 KB Add to Briefcase
Showing 1-20 of 605 Page: 1 2 3 4 5 ... 31  Next 20
Add to Briefcase = add release to Briefcase
Print E-mail